OUTLOOK THERAPEUTICS, INC. Expense Breakdown
No Expense Breakdown for OTLK on this site yet.
- 2026-06-30: Development and Commercialization Of Ons-5010 Or Lytenava $16.96K.
- 2025-06-30: Development and Commercialization Of Ons-5010 Or Lytenava $439.81K.
Source checked: the stored Expense Breakdown page for OTLK.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ons-5010 Or Lytenava |
|---|
| 2026-06-30 | $16.96K |
|---|
| 2025-06-30 | $439.81K |
|---|
Research and development: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ons-5010 Or Lytenava |
|---|
| 2026-06-30 | $3.25M |
|---|
| 2025-06-30 | $7.13M |
|---|
Research And Development Expense Compensation And Related Benefits: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ons-5010 Or Lytenava |
|---|
| 2026-06-30 | $567.19K |
|---|
| 2025-06-30 | $906.20K |
|---|
Research And Development Expense Ons5010Or Lytenava Development: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ons-5010 Or Lytenava |
|---|
| 2026-06-30 | $2.19M |
|---|
| 2025-06-30 | $5.85M |
|---|
Research And Development Expense Stock Based Compensation: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ons-5010 Or Lytenava |
|---|
| 2026-06-30 | $63.27K |
|---|
| 2025-06-30 | $91.64K |
|---|
Selling, General and Administrative Expense: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ons-5010 Or Lytenava |
|---|
| 2026-06-30 | $7.55M |
|---|
| 2025-06-30 | $9.68M |
|---|